(Q35522668)

25219291

8 August 2017

title

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C (English)

1 reference

cost-effectiveness analysis

8 August 2017

0 references

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

H Leleu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M Blachier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

15 September 2014

1 reference

25219291

Journal of Viral Hepatitis

8 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

376-383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Sofosbuvir for previously untreated chronic hepatitis C infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Telaprevir for previously untreated chronic hepatitis C virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Treatment of patients with hepatitis C and cirrhosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Epidemiology of hepatitis C

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4406130

Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis

12 July 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations

21 January 2018

1 reference

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).

21 January 2018

1 reference

Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study

21 January 2018

1 reference

Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication

21 January 2018

1 reference

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial

21 January 2018

1 reference

Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection

21 January 2018

1 reference

Continuity of care -- a chameleon concept

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25219291

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/JVH.12311

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

25219291

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219291%20AND%20SRC:MED&resulttype=core&format=json